Just caught XRTX jumping over 40% overnight after news dropped about their renal anti-fibrotic program acquisition from Vectus Biosystems. The stock hit $0.68 which is wild considering it closed at $0.49 the day before. Apparently they're extending the deal closure to March 31, 2026 to sort out IP transfers, but investors seem pretty pumped about it.

So basically they're picking up this drug candidate called VB4-P5 that targets kidney diseases - still early stage (pre-IND) but could be interesting for both rare and common kidney conditions. The original deal was $3 million back in October, priced at $0.86 per share. Pretty typical biotech move, but the stocks market really liked the announcement.

XORTX has got a few other programs going too - stuff for gout, ADPKD, and acute kidney injury. Their shareholder meeting is coming up March 24, 2026 if you're tracking these stocks. Curious to see if this momentum holds or if it's just the usual biotech hype cycle.